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Abstract
Objectives: To assess outcomes following cochlear implantation (CI) in patients with
hearing loss secondary to primary or secondary autoimmune inner ear dis-
ease (AIED).
Methods: A systematic review and narrative synthesis was completed according to
PRISMA guidelines. Databases searched included MEDLINE, PubMed, EMBASE,
Web of Science, Cochrane Collection, and ClinicalTrials.gov. No limits were placed
on year of publication or language.
Results: A total of 551 studies were identified, of which 29 were included after
removal of duplicates, and screening the title, abstract, and full text. All except one
study were OCEBM grade IV. 114 of 115 patients displayed improvement in hearing
following cochlear implantation. With implant use, roughly a third of these patients
had hearing that improved over time, a third improved and plateaued, and a third
remained stable. There was no additional risk of perioperative complications found in
AIED patients compared what is generally accepted in general cochlear implantation,
although two episodes of device failure after 6 months were noted, and four patients
with secondary AIED displayed poor initial audiological outcomes.
Conclusion: CI in both primary and secondary AIED provides marked improvement in
hearing. Early CI may be a valid management option, provide long-lasting hearing in
patients and reduce the side effects of long-term systemic immunosuppressants.
However, patients should be counseled residual hearing may be lost if there is
cochlear ossification or fibrosis which may make implant insertion more traumatic.
Level of Evidence: NA.
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1 | INTRODUCTION
Autoimmune inner ear disease (AIED) is a rare disease that can lead to
profound bilateral SNHL.1,2 As well as being very uncommon, com-
prising <1% of all hearing loss or dizziness,3 the diagnosis of AIED
may be difficult due to its masked clinical presentation by its underly-
ing etiology. AIED can be categorized into primary or secondary cau-
ses. Where the autoimmune process is limited to the cochlea or
vestibular system, this condition is termed primary AIED. It is esti-
mated that up to a third of all AIED is secondary AIED, that is, hearing
loss as a consequences of a wider systemic autoimmune disease.2-4
This includes an extensive differential list that includes, but is not lim-
ited to, Cogan's syndrome,5 Vogt Koyanagi Harada (VKH) syndrome,6
granulomatosis with polyangiitis,7 systemic lupus erythematosus
(SLE),8 polyarteritis nodosa (PAN),9 relapsing polychondritis, inflamma-
tory bowel disease (IBD), rheumatoid arthritis (RA),10 and Sjögren's
syndrome.11
1.1 | Diagnosis
Although several autoantibodies have been postulated, some of
which may predict response to steroid treatment, no specific diag-
nostic marker for AIED has been identified.3,12 The mainstay of diag-
nosis therefore is through clinical history, examination, and
characteristic response to steroids and immunosuppressants.1 This
clinical presentation was first noted by McCabe in 197213 when he
noted that AIED patients tended to display a bilateral and asymmet-
rical hearing loss that was progressive or fluctuating, occurring over
weeks to months, and responsive to steroids. When diagnosing
AIED, it is critical to rule out systemic autoimmune causes before a
diagnosis of primary AIED is made, as this may affect treatment and
prognosis. Blood tests, therefore, should screen for causes of sec-
ondary AIED and may include a full blood count (FBC), erythrocyte
sedimentation rate (ESR), anti-double stranded DNA (dsDNA), rheu-
matoid factor (RF), Anti-Neutrophil Cytoplasmic Antibodies (ANCA),
C3 and C4 complement levels, and Human Immunodeficiency Virus
(HIV) testing.2
1.2 | Pathophysiology
There are various theories as to the pathophysiology underlying AIED.
Currently, the favored theory is that of humoral and cell-mediated
self-targeting of antigens within the inner ear.2,12,14 These antigens
may have been introduced as a result of systemic, or direct damage to
the cochlea leading to a type 1 T helper (Th1) cell response and subse-
quent tissue damage via autoantibody formation and/or immune-
complex deposition.14 This is supported by studies in rats, whereby
labyrinthitis was induced experimentally after introducing a systemic
inner ear antigen.15
1.3 | Current treatment
The mainstay of treatment is pharmacological: oral steroids,
intratympanic (IT) steroids, and methotrexate (MTX) seem to be most
widely used. Other treatments such as azathioprine (AZA) and plasma-
pheresis have also been trialled.1,12 More recently, various biologics
both systemically and intratympanically have been tested. There is lit-
tle consensus as to the most effective treatment.16 In some cases,
however, the progressive nature of the AIED results in the need for
hearing aids and/or cochlear implantation due to failure of medical
therapy.12
1.4 | Risks of cochlear implantation
It is thought that CI confers good patient benefit,1,2 however given
the scarcity of AIED cases, data for CI in this group is lacking. There
are no additional risks universally accredited to AIED beyond what is
already accepted for cochlear implantation in the current literature.17
Importantly, some patients with AIED have been noted to develop
ossification of the cochlea8 which could affect the surgical placement
of CI electrodes, that is, partial, difficult or more traumatic insertion,
which could further result in more frequent loss of residual hearing.18
Hearing loss in AIED may also fluctuate, making diagnosis and hearing
rehabilitation more challenging.
1.5 | Objectives
The aim of this review was to compile documented cases of CI in
AIED patients, to assess the pre- and post-operative hearing out-
comes, note any significant perioperative complications, and to ulti-
mately evaluate the benefit of this intervention for this challenging
patient group.
Population: Children or adults with systemic or inner ear autoim-
mune hearing loss.
Intervention: Cochlear implantation.
Comparison: No formal comparison, may demonstrate intra-
subject change pre and post-operatively or report outcomes com-
pared to non-AIED patients.
Outcomes: Pre- vs post-implantation audiometric outcomes with
cochlear implant usage (where pre-implantation outcomes were not
available, only post-implantation audiometric outcomes were
included). Complications associated with perioperative period in
patients receiving cochlear implantation.
2 | MATERIALS AND METHODS
The study protocol was registered in the PROSPERO prospective
database of systematic reviews (CRD42021229196).
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2.1 | Study inclusion criteria
Clinical studies of cochlear implantation in patients with hearing loss
secondary to primary or secondary autoimmune inner ear disease
(AIED), where hearing outcomes were reported at 3 months (or later)
post-implantation. Studies of any experimental or observational
design in humans were included. Animal and human studies without a
report of postoperative audiometric outcomes or where the abstract
or full text was unavailable were excluded. Diabetes and multiple scle-
rosis were not included in the search strategy, as the effects are likely
not due to primary autoimmune disease in the inner ear.
2.2 | Search strategy
JL performed the searches, which was rechecked by a clinical librarian.
In total, 2 reviewers (JL/KB) independently screened the abstracts.
The following databases were searched: MEDLINE, PubMed,
EMBASE, Web of Science, Cochrane Collection, and ClinicalTrials.gov.
The search terms used can be found in Appendix 1.
No limit was placed on language or year of publication.
2.3 | Selection of studies
Searches were performed by JL. Two reviewers (JL/KB) independently
screened all the records by title and abstract identified from the data-
base searches. Studies describing cochlear implantation in patients
with systemic or inner ear autoimmune hearing loss were assessed
against the inclusion and exclusion criteria, with any disagreement
resolved by discussion with a third reviewer (JM).
Studies without accessible full text after screening the title and
abstract were gathered by contacting the respective study authors. If
they remained unavailable or the author did not reply, the study was
excluded. Studies were excluded if they did not report post-
intervention audiometric outcomes 3 months (or later) post-procedure.
Potentially relevant studies identified from the initial searches and
abstract screening then underwent full-text screening by the two inde-
pendent reviewers before data extraction. Conflicts on the selection
were resolved by discussion between the reviewers.
2.4 | Data extraction
Data were extracted by the first reviewer (JL) and then checked by a
second reviewer (KB). Extracted data were arranged in a spreadsheet
(Excel, Microsoft Corp., Redmond, Washington).
2.5 | Risk of biased quality scoring
Two reviewers independently assessed the risk of bias using the
Brazzelli risk of bias tool for non-randomized studies.19 Studies were
also graded according to the Oxford Centre for Evidence-Based Medi-
cine (OCEBM) grading system.20 Discrepancies between the
reviewers were resolved by discussion.
3 | RESULTS
Searches were first performed on the 30th of December 2020, and
re-checked on the 16th of January 2021. A total of 551 records
were identified, of which 309 remained after removing duplicates
(Figure 1). A further 250 studies were excluded by abstract and
title screening, and 30 full text articles were excluded due to the
following reasons; no audiometry after 3 months stated (n = 19),
no access to full text from author (n = 4), poster or oral presenta-
tion (n = 2), data pooled with other non-autoimmune group results
(n = 2), no cochlear implantation (n = 2), no autoimmune dis-
ease (n = 1).
Studies took place between 1996 and 2021, consisting of 20 sin-
gle case reports, 4 case series, 3 cohort studies, 1 case-control study,
and 1 chart review.
There were a total of 115 patients of which there was a female
preponderance (77 females, 38 males). Ages ranged from 4 to
84 years at the time of implantation, and the time from symptoms to
cochlear implantation ranged widely from 1 to 120 months. A minor-
ity of patients had primary AIED (38) compared to secondary AIED
(77) such as Cogan's syndrome (n = 42), relapsing polychondritis
(n = 6), ANCA-associated vasculitis (n = 4), rheumatoid arthritis (n = 3),
granulomatosis with polyangiitis (n = 3), inflammatory bowel disease
(n = 2), Vogt-Koyanagi-Harada syndrome (n = 2), polyarteritis nodosa
(n = 2), unspecified vasculitis (n = 2), eosinophilic granulomatosis with
polyangiitis (n = 1), Beçet's disease (n = 1) cerebral vasculitis (n = 1),
Sjögren's syndrome (n = 1), primary sclerosing cholangitis (n = 1),
neurosarcoidosis (n = 1), systemic psoriasis (n = 1), systemic lupus
erythematosus (n = 1), Sweet's disease (n = 1), chronic demyelinating
inflammatory polyneuropathy (n = 1), and systemic sclerosis (n = 1).
Diagnosis was mostly clinical, however one study21 conducted genetic
tests to rule out other causes (Muckle-Wells syndrome). Common pre-
senting symptoms included vestibular symptoms (26% of patients
reporting dizziness, vertigo, or unsteadiness) and tinnitus (18%). This
was much lower than estimated by Vambutas et al, Mijovic et al, and
Bovo et al, who estimated half of all AIED patients display vestibular
symptoms and a quarter to half displayed tinnitus,2,3,12,22 however
this may just be due to an omission of reporting in studies. Other
symptoms appear more related to the systemic autoimmune condition
such as keratitis in Cogan's syndrome,23 or sclerodactyly in systemic
sclerosis.24
Apart from three studies,11,25,26 details on implant type were
given. A minimum of 9 patients were recorded to have bilateral
cochlear implants, however this number may be an under-
representation as some studies did not disclose if there was unilat-
eral or bilateral implantation. Follow-up durations after surgery
varied between 3 months - 16 years. Study characteristics are
summarized in Table 1.
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3.1 | Quality of studies
All studies were retrospective and tended to have a small population
size. Owing to the rare nature of AIED, the majority of the studies
were single case reports or uncontrolled case series, and therefore
Oxford Centre for Evidence-Based Medicine (OCEBM) grade IV, with
the exception of one retrospective cohort study with randomised con-
trols that was OCEBM grade III.8 There was significant heterogeneity
between the various studies' reporting of pre- and post-operative
audiometric evaluations, surgical technique, and follow-up manage-
ment, which prevented meta-analyses. A tabular representation of the
Brazzelli risk of bias is presented in Table 2. The majority of the
studies had a high risk of bias in selecting representative samples, lack
of clarifying inclusion and exclusion criterias, and method of
patient selection and data collection (mostly restrospective and
nonconsecutive patients). Most studies did not disclose the center's
facilities or expertise in conducting cochlear implantation. All studies
considered important outcomes and objective outcome measures
(as required in the inclusion criteria).
3.2 | Audiological outcomes
Hearing outcomes (Table 3) were mostly positive across the studies
with the exception of 4 patients: case 3 (Cogan's syndrome, Cochlear
Nucleus 24k, unknown if full insertion) in Bovo et al,27 and cases 1, 2
and 4 (3 ANCA-associated vasculitis patients, unknown CI device or
whether full insertion) in Watanabe et al.26 Reported outcome mea-
sures were heterogeneous throughout, with over 20 different audio-
metric outcome measures being used across the various studies; some
even using different combinations within the same study pre- and
post-operatively. All studies revealed pre-operative hearing assess-
ments, of which 13 specifically mentioned pure tone audiometry
(PTA), all showing severe to profound hearing loss or anacusis. Three
F IGURE 1 PRISMA (2009)
flow diagram
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patients Population Autoimmune disease Study type
OCEBM*
Grade
Abou-Elhmd et al7 1996 UK 1 Adult GPA Retrospective Case report IV
Aftab et al8 2010 US 10 Adult Primary AIED (8), Lupus (1),
Psoriasis (1)
Retrospective chart review III




Retrospective Case report IV
Aschendorff
et al24
2004 Germany 6 Adult Cogan's syndrome Retrospective Cohort
study
IV
Bacciu et al25 2015 Italy 12 Adults Cogan's syndrome Retrospective case series IV
Bovo et al26 2011 Italy 3 Adults Cogan's syndrome Retrospective case series IV
Cacco et al27 2021 Italy 1 Adult eGPA Retrospective case report IV
Canzi et al9 2019 Italy 1 Adult Polyarteritis nodosa Retrospective case report IV
Cassis et al28 2018 US 1 Adult Cogan's syndrome Retrospective case report IV
Cheng et al29 2010 Australia 1 Adult Sweets disease Retrospective case report IV
Dhanjal et al30 2014 UK 1 Adult Neurosarcoidosis Retrospective case report IV
Im et al31 2008 South
Korea
1 Adult Cogan's syndrome Retrospective case report IV
Kamakura et al32 2017 US 1 Adult Cogan's syndrome Retrospective case report IV
Kawamura et al32 2010 Japan 1 Adult Cogan's syndrome Retrospective case report IV
Kontorinis et al22 2010 Germany 4 Mixed Cogan's syndrome Retrospective case series IV
Low et al21 2019 Singapore 1 Adult Cogan's syndrome Retrospective case report IV
Low et al33 2000 Singapore 1 Adult Cogan's syndrome Retrospective case report IV
Malik et al11 2012 US 26 Adults Primary IED (16), Cogan's
syndrome (2), RP (3),
Sjögren (1), RA (1), PSC (1),





Mowry et al34 2017 US 1 Adult Chronic demyelinating
inflammatory
polyneuropathy
Retrospective case report IV
Patrizia et al35 2011 Italy 1 Adult RP Retrospective case report IV
Psillas et al36 2007 Greece 1 Adult Polyarteritis nodosa Retrospective case report IV






Salahaldin et al38 2010 Qatar 1 Child Primary AIED Retrospective case report IV
Santarelli et al39 2006 Italy 1 Adult Systemic sclerosis Retrospective case report IV
Seo et al40 2012 South
Korea
1 Adult RP Retrospective case report IV
Sweetow et al41 2005 US 1 Child RA Retrospective case report IV
Sydlowski et al42 2014 US 1 Adult Vogt-Koyanagi-Harada
syndrome
Retrospective case report IV
Wang et al10 2010 Canada 25 Adult Primary AIED (13), Cogan's
syndrome (7), RP (1), RA
(1), GPA (1), 1 UC (1)
Crohns disease (1)
Retrospective case control IV
Watanabe et al23 2018 Japan 4 Adult ANCA-associated vasculitis Retrospective case series IV
Abbreviations: ANCA, antineutrophil cytoplasmic antibody; GPA, granulomatosis with polyangiitis; eGPA, eosinophilic granulomatosis with polyangiitis;
PSC, primary sclerosing cholangitis; RA, rheumatoid arthritis; RP, relapsing polychondritis; UC, ulcerative colitis.
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studies additionally also reported otoacoustic emission testing pre-
operatively, all reporting no response, which would suggest that the
diseases primarily affect the cochlea and not the auditory nerve.6,28,29
With the exception of Aschendorff (who did not report post-op
TABLE 2 Tabular representation of Brazzelli19 risk of bias tool
Authors 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Abou-Elhmd et al, 1996
Aftab et al, 2010
AlHelali et al, 2019
Aschendorff et al, 2004
Bacciu et al, 2015
Bovo et al, 2011
Cacco et al, 2021
Canzi et al, 2019
Cassis et al, 2018
Cheng et al, 2010
Dhanjal et al, 2014
Im et al, 2008
Kamakura et al, 2017
Kawamura et al, 2010
Kontorinis et al, 2010
Low et al, 2019
Low et al, 2000
Malik et al, 2012
Mowry et al, 2017
Patrizia et al, 2011
Psillas et al, 2007
Quaranta et al, 2002
Salahaldin et al, 2010
Santarelli et al, 2006
Seo et al, 2012
Sweetow et al, 2005
Sydlowski et al, 2014
Wang et al, 2010
Watanabe et al, 2018
Note: Green = Yes (low risk of bias); Red = No (high risk of bias); Yellow = unclear (unclear risk of bias); Gray = Not applicable.
1. Were participants a representative sample selected from a relevant patient population?
2. Were the inclusion/exclusion criteria of participants clearly described?
3. Were participants entering the study at a similar point in their disease progression?
4. Was selection of patients consecutive?
5. Was data collection undertaken prospectively?
6. Were the groups comparable on demographic characteristics and clinical features?
7. Was the intervention (and comparison) clearly defined?
8. Was the intervention undertaken by someone experienced at performing the procedure?
9. Were the staff, place, and facilities where the patients were treated appropriate for performing the procedure?
10. Were any of the important outcomes considered (ie, on clinical effectiveness, cost-effectiveness, or learning curves)?
11. Were objective outcome measures used, including satisfaction scale?
12. Was the assessment of main outcomes blind?
13. Was follow-up long enough (≥1 year) to detect important effects on outcomes of interest?
14. Was information provided on non-respondents, dropouts?
15. Were the characteristics of withdrawals/dropouts similar to those that completed the study and therefore unlikely to cause bias?
16. Was length of follow-up similar between comparison groups.
17. Were the important prognostic factors identified?
18. Were the analyses adjusted for confounding factors?
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TABLE 3 Audiological outcomes
Authors
Patients








1(1) Right: Initially SNHL of
30-50 dB, then no PTA
response over 22 months
Left: Initially mixed hearing loss
of 80-90 dB then no PTA
response
9 months post-op:
Right (implanted ear): PTA:
40 dB hearing loss- BKB:
20%




CDT score: 74 words/3
minutes





10(12) Mean preoperative PTA: 90
± 13 dB
Mean SRT 77.9 ± 38 dB
Mean ST (short term <12mo)
SRT: 24 ± 7 dB
Words scores 11% ± 17%
Sentence score was 11% ± 15%
Sentence scores were determined
by hearing in noise testing,
except in 3 patients where the
CID Everyday Sentence test was
used.
<12 months post-op
Word score: 74% ± 15%
Sentences score: 94% ± 6%
≥12 months post-op
Word score: 87% ±11%
Sentences score: 96% ±4%
Good improvement in word
scores at short term
(<12 months) follow-up,







1(2) SRT: 45 dB SPL (sound field) in
the better earSDS: 0% at
100dBSPLOAE: Absent
response bilaterallyPTA:
profound to no hearing
bilaterally.
5 years post-op
SRT: 25 dB HL bilaterally
SDS: 84% (Right), 72% (Left)
without visual cues.
SDS: 100% with visual cues.
CAP: 8
Speech intelligibility rating: 5









Results available for 3 cases
only













All language tests were
performed in listening mode
with CI at 70 dB SPL
All cases with reported
outcomes showed good to
excellent response compared
to pre-op, however the
authors did not present half
of the study populations




12(X) All patients exhibited either
complete deafness or a
bilateral profound SNHL.
Mean WRS: 9.7% (range 0-30%)
Mean SRS: 10.9% (range 0-48%)
12 months post-op
Mean WRS: 91.4% (range
75-100%)
Mean SRS: 93.1% (range
76-100%).
5 years post-op
Mean WRS: 94% (range
85-100%)
Mean SRS: 96.3% (range
90-100%).
Excellent lasting response that















3(5) Case 1: Profound bilateral
deafness permitting only
detection of words.
Case 2:40% word recognition in
closed set word
identificationCase 3: Sudden
hearing loss in high
frequencies, closed set word
identification of 50%
Case 1
- 3 months post-op: WRS(open
set): 80-90%
- 6 months post-op: able to use
the telephone with family
members
- Electrodes 1-4 became faulty
secondary to increased
electrical impedance, and
closed set WRS fell to 80%,
while the aided threshold
corresponded to 30 dB for
the frequencies between
0.25 and 4 KHz.
Case 2
- 3 months post-op: open set
WRS 90%
- 28 months post-op: no
significant variation in
electrical impedance of any
of the electrode and good
functional results unchanged.
Case 3
- 3 months post-op: aided
threshold of 30 dB from 0.25
to 4 kHz.
- Only reached a closed set
word identification
performance up until follow
up at 42 months
Good response in Case 1 and 2,
however case 3 does not
display any benefit, and case
1 may decline in the future





1(1) Right: PTA (Profound SNHL)
80 dB 125 Hz, 90 dB 250 Hz,
95 dB 500 Hz, 95 dB 1 kHz, no
response in higher frequencies.
Left: PTA: (severe SNHL with
hearing remnants) No
response except 100 dB at
250 Hz and 120 dB at 500 Hz.
- SRT: No response
- WRS: was 0% at 100 dB nHL.
- ABR: demonstrated a
destructured path and absence
of recognizable waves.
18 months post-op
- PTA: 50 dB 125 Hz, 40 dB
250 Hz, 35 dB 500 Hz,
30 dB 1 kHz, 30 dB 2 kHz,
40 dB 4 kHz, 40 dB 8 kHz.
- WRS 50% at 60 dB nHL




1(2) Right: Severe hearing loss with
PTA in the 0.5-2 kHz frequency





Right: PTA of 40 dB HL
- SRS in quiet: 80% at 70 dB HL
Left: PTA: 60 dB HL





1(2) Profound bilateral hearing loss








1(1) PTA: near-symmetrical, severe to





- In quiet (65 dB SPL):99%
- In noise: 41%
Right PTA: Aided average
across four frequencies (0.5,
1, 2 and 4 kHz) was 23.75 dB
Good response Not stated.
≥3












1(1) Bilateral: Profound bilateral
sensorineural hearing loss
- ABR: no response
- Amplification aids provided no
improvement in his symptoms.
Right: Three thresholds at
115 dB in the mid frequencies
on the right.
- CUNY speech perception
tests*: 2.8% with sound and lip
reading.
Left: one recordable threshold at
1 kHz
*measured at 70 dB(A) in quiet
4 months post-op
BKB sentence testing with




1(1) Total bilateral deafness 1 year post-activation
Mean open-set word tests:
91%





1(2) Right: PTA: 90 dB, Severe to
profound SNHL













1(1) Bilateral: Profound SNHL
- Speech audiometry: no
response.











4(6) Case 1: Right PTA* 83, AEP 90.
Case 2: Right PTA* 100, AEP 100
// Left PTA* 77 AEP 80.
Case 3: Left PTA* 93, AEP 90
Case 4: Right PTA* 100 // Left
PTA* 100
*Mean hearing threshold of 0.5, 1,
2 and 4 kHz
Case 1: 12 months speech
tracking 86.6, MS 90%, N
100%, HSMs 84.94, HSM
(10) 3.66.
- 16 years post-op ST 78.6w/
m, MS 90%, N 100%,
HSMs100%, HSM(10)39.67
Case 2: 12 months ST 74w/m,
MS 85%, N 100%, HSMs
99.06 seconds, HSM (10)
44.33.
- 12 years post-op ST70.6w/m,
MS 95%, N 100%, HSMs
100, HSM(10)34.9.
Case 3: 12 months ST 30.6w/
m, MS 70%, N 100%, HSMs
86.8.
- 8 years post-op ST 42.8w/m,
MS 65%, N 100%, HSMs
87.7, HSM (10) 2.8
Case 4:12 months MS 70%, N
100%, HSMs 99.1, HSM (10)
31.13.
All cases:
- Mean HSMs 12 months post-
op: 95.05%
- Mean HSMs final latest
follow-up: 96.7%














- Freiburg Monosyllabic Word
Test: 100% across all time
periods
- All patients enjoyed high
levels of speech recognition
and were able to use the
telephone without any
difficulties.
- Bilateral CI (case 2 and 4), and
bimodal CI (case 1) had






1(2) Bilateral profound hearing loss <3 months post-op: Speech test:
90%
3 months post-op: right ear
reduced hearing with otalgia
3 years post op: speech test:
83% (Right), 0% (Left)
Very good response initially,





1(1) Profound hearing loss
AB word list: 0%
BKB sentences (closed-set): 0%
3 months post-op
- AB word list: 31%
- BKB sentences (closed-set):
72%







6 to 11 months post-op
HINT-Q (mean ± SD): Primary
AIED 14.8 ± 23.4, Secondary
AIED 75.7 ± 24.9)
CNC-W(mean ± SD): Primary
AIED 9.1 ± 12.1, Secondary
54.4 ± 25.5
CNC-P(mean ± SD): Primary
19.4 ± 21.0 and Secondary
71.7 ± 17.9.
12 to 17 months post-op
HINT-Q: Primary AIED scores
higher than secondary by
average of 15.52, otherwise
hearing remained generally
stable.
Good response in Secondary
AIED <12 months with
minimal to no improvement
in Primary AIED; However,






1(1) PTA: No response
AzBio: 0%
ABR: No response
6 months post-activation: AzBio:
21%
1 year post-activation: AzBio:
40%
18 months post-activation:
AzBio: 35%, Ling sounds:
67%
Poor to moderate response 18
Patrizia et al,
2011
1(1) Rapidly progressive bilateral
SNHL
4 years post-op: 100% bisyllabic
word and sentences
recognition in quiet and at
SNR +10.
13 years post-op: Words and
sentences in quiet 100%,
SNR +10 words 70%,
sentences 80%. CAP = 6 able
to understand conversation
without speech reading.
Excellent lasting response 156











1(1) PTA: No response













5(X) Case 1: Anacusis, SDS 0%
Case 2: PTA 100 dB SDS 0%
Case 3 Anacusis, SDS 0%
Case 4 Anacusis SDS 0%
Case 5 PTA 500 dB, SDS 10%.
Case 1:
- 2-syllable word recognition*:
3 months: 45, 1 year: 70,
2 years: 75—Sentences:
3 months: 65, 1 year: 100,
2 years: 70
- Speech tracking: 3 months:
17, 1 year: 46, 2 years: 26.
Case 2:
- 2-syllable word recognition:
3 months: 50, 1 year: 70,
2 years: 90
- Sentences: 3 months: 30,
1 year: 100, 2 years: 100
- Speech Tracking: 3 months:
23, 1 year: 50, 2 years: 68
Case 3:
- 2 syllable word recognition:
3 months: 60, 1 year: 90,
2 years: 70
- Sentences: 3 months:90,
1 year: 100, 2 years: 90
- Speech tracking: 3 months:
27, 1 year: 45, 2 years: 46
Case 4:
- 2 syllable word recognition:
3 months: 90, 1 year: 100
2 years: 80
- Sentences: 3 months: 90,
1 year: 100, 2 years: 95
- Speech tracking: 3 months:
33, 1 year: 36, 2 years: 46
Case 5:
- 2 syllable word recognition:
3 months: 60, 1 year: 90,
2 years: 80
- Sentences: 3 months: 70,
1 year: 100, 2 years: 90
- Speech tracking: 3 months:
25, 1 year: 45, 2 years: 47.
Average results
(3 months;1 year; 2 years):
- Open set 2-syllable word
recognition (61;84;79)
- Sentence scores (69;100;89)
- Speech Tracking
(25;44.5;46.6)
*Number of words correctly
repeated in 1 minute
Moderate to excellent
response that generally






1(2) ABR: normal. No clear response
to maximum stimulation of





- FF testing: 45, 40, 25, 35,
40 dB at 0.25, 0.5, 1, 2, and
4 kHz.
Excellent response from left













- DS score: 50% at 90 dB level
5 years post-op
Left:
- FF testing: 10, 15, 15, 20,
25 dB at 0.25, 0.5, 1, 2, and
4 kHz





1(1) Bilateral: hearing loss that
worsened with higher
frequencies.
Right: 35 dB 125 Hz, 45 dB
250 Hz, 80 dB 500 Hz, 95 dB
1 kHz, 95 dB 2 kHz.
Left: 30 dB 125 Hz, 35 dB
250 Hz, 32 dB 500 Hz, 45 dB
1 kHz, 85 dB 2 kHz and no
response at higher frequencies.
- Disyllabic words 100%.
- Trisyllabic words 15%
- Sentences 20%
- TIPI1 50%




- Disyllabic words 75 ± 20%
- Trisyllabic words 89 ± 12%
- Sentences 96 ± 7%
- TIPI1 95%






1(1) ABR: No response
DPOE: No response
CAP score: 0
- MS word DS 0% without lip
reading
- Sentence DS: 17%
Aided audiogram showed a
40 dB threshold through all
frequencies.
4 months post-op
- CAP score: 5
- MS word DS: 90% with lip
reading, 40% without it.
- Sentence DS: 92%






1 Right: profound hearing loss,
WRS 0%
Left: severe to profound loss,
WRS 0%
Acoustic reflexes and OAE:
Absent.




- open set PBK-50s: 82% at
55 dB HL without visual
cues.





1(2) Right: PTA moderate to severe:
55 dB (250 Hz), 60 dB
500 Hz), 65 dB (1 kHz), 55 dB
(2 kHz), 60 dB (3 kHz), 70 dB
(4 kHz) 85 dB (6 kHz + 8 kHz)
Left: PTA No response.
6 months post-activation
Right: CNC-P: 93%, CNC-W:
80%, AzBio (quiet): 99%,
AzBio (+10 dB SNR) 80%,
BKB-SIN SNR50: 6.5, SNR
loss 9, Degree: moderate
Left: CNC-P: 92%, CNC-W:
84%, AzBio (quiet): 97%,
AzBio (+10 dB SNR) 81%,
BKB-SIN SNR50: 6.5, SNR
loss: 9, Degree: moderate
Bilateral: CNC-P: 96%,
CNC-W: 88%, AzBio (quiet):
99%, AzBio (+10 dB SNR)
88%, BKB-SIN SNR50: 1.5,
SNR loss: 4, Degree: mild
Very good to excellent
response
12
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outcomes in 3 of 4 cases),30 all studies gave post-operative audiomet-
ric data for each individual case or as an average. Multiple heteroge-
neous outcome measures were used (see Table 3 for list).
No studies reported any standardized measures of patient
reported outcomes. Aftab et al8 conducted the only study with a ran-
domized control group, and furthermore conducted the only statistical
analysis. This revealed no difference in postoperative audiometric out-
comes between patients with or without AIED after CI.
3.3 | Surgical outcomes
Four patients of 115 were reported to have had immediate complica-
tions; Wang10 mentioned one intraoperative CSF leak (unspecified
etiology of AIED as in a mixed group) which was successfully repaired
with fascia, and a further patient (case 3, unknown etiology of AIED)
that developed minor wound dehiscence that required topical antibi-
otic cover. Kontorinis25 similarly reported a case (Cogan's syndrome)
with recurrent skin infections that was treated with antibiotics, and
Low31 reported a patient (Cogan's syndrome) with scalp pressure sore
from the dressing that healed conservatively. Other reports not within
the immediate post-operative period (>6 months, or time not
reported) include: CI failure (n = 2, one of which had Cogan's syn-
drome, and the other was not specified in a mixed group),10,30 facial
tactile sensations (n = 1, Cogan's syndrome),27 and worsening facial
pain with reduced hearing bilaterally (n = 1, Cogan's syndrome).21 The
remainder of the studies did not state any surgical complications, and
Bacciu23 explicitly stated that none of their patients suffered from
complications from their flap or systemic disease.
3.4 | Inner ear ossification
In Aftab's 12 implanted ears, 6 showed intraluminal fibrosis and neo-
osteogenesis (of mixed aetiology).8 Bacciu noted that this ossification
may not be identified on pre-operative imaging, with 3 cases having
clear imaging but findings of intraoperative osteogenesis23 (all











25(27) Open set sentence score (mean
± SD, %) 7 ± 12.3
Open set sentence score (mean
± SD):
- 6 months: 92.8 ± 12.1
- 1 year: 97.3 ± 5.3
- >2 years = 96.4 ± 4.9






- Right: No response.
- Left PTA 90 dB (500 Hz) 65 dB
(1 kHz), 70 dB (2 kHz), 85 dB
(4 kHz).
Case 2: Bilateral total deafness
Case 3:
- Right PTA 50 dB (125 Hz),
60Db (250 Hz), 70 dB
(500 Hz), 75 dB(1 kHz), 80 dB
(2 kHz), 90 dB (4 kHz), No
response (8 kHz).
- Left PTA 45 dB (125 Hz), 55Db
(250 Hz), 60 dB (500 Hz),
65 dB(1 kHz), 80 dB(2 kHz),
85 dB (4 kHz), 100 dB (8 kHz).
Case 4: Bilateral total deafness
Case 1:
- Word recognition: 8% (60%
with auditory and visual
data)
- Sentence recognition: 3%
(52% with auditory and
visual data)
Case 2:18 months post-op:
(poor response)
- MS recognition: 18%
- Word recognition: 40%
- Sentence recognition: 40%
Case 3: (good response)
- MS recognition: 90%
- Word recognition: 100%
- Sentence recognition: 100%
Case 4: (poor response)
- MS recognition: 0%
- Word recognition: 0%
- Sentence recognition: 0%
Poor response in Case 1, 2, 4.
Good response in Case 3;
however poor reporting of
follow-up times, and
therefore this may have
improved over time, or been








Abbreviations: AB, Arthur Boothroyd isophonemic monosyllabic word test; ABR, Auditory Brainstem Response test; AEP, Auditory Evoked Potential;
AzBio, Arizona state university sentences; BAER, Brainstem Autiroy Evoked Response; BKB, Bamford-Kowal-Bench sentence testing; CAP, Categories of
Auditory Performance; CDT, Connected Discourse Tracking; CNC, Consonant Nucleus Consonant scores; CNC-W, CNC Word; CNC P, CNC Phonemes;
CUNY, City University of New York; DPOE, Distortion Product Otoacoustic Emissions; DS, discrimination score; FF, free field testing; HINT-Q, hearing in
noise sentence test presented in quiet; HSM, Hochmair-Schulz-Moser sentence test; HSMs, HSM test in quiet; HSM 10, HSM test at 65 dB with 55 dB
surrounding noise; MS, Monosyllabic; N, numbers; nHL, Normal Hearing Level; OAE, Otoacoustic emissions; PBK, Phonetically Balanced Kindergarten
(word recognition test); PTA, Pure Tone Audiometry; SAT, Speech Awareness Threshold; SDS, Speech Discrimination Score; SIN, Speech In Noise; SNHL,
Sensorineural Hearing Loss; SNR, Signal to Noise Ratio; SPL, Sound Pressure Level; SRS, Sentence Recognition Score; SRT, Speech Recognition Threshold;
ST, Speech Tracking; TIPI1, Test di Identificazione Parole Infantili 1 (childhood word identification test-1); VCV, Vowel-Consonant-Vowel; WIPI, Word
Intelligibility by Picture Identification Test; w/m, words per minute; WRS, Word Recognition Score.
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mentioned intra-operative findings, 53.5% (23 patients) were found to
have unilateral or bilateral fibrosis or osteogenesis of a section of the
cochlea (14 Cogan's syndrome, 1 Vogt-Koyanagi-Harada syndrome,
1 neurosarcoidosis, 1 PAN, 6 not specified),6,8,9,23,28,30-35 10 of which
required a drill out (7 Cogan's syndrome, 1 PAN, 2 unknown).8,9,23,28,31
8,9,23,28,31 In 6 patients, electrodes were still unable to be placed
within the scala tympani (ST) and therefore the scala vestibuli
(SV) was used (4 Cogan's syndrome, 1 Vogt-Koyanagi-Harada syn-
drome, 1 neurosarcoidosis).6,23,30,32 Despite findings that SV insertion
is traumatic to the cochlea and has a higher risk of loss of residual
hearing,18 all studies with implantation into the SV reported good or
excellent hearing outcomes post CI, although Aschendorff et al30 did
not fully disclose the data for all of their patients, and so it is not
known if the three reported include those with electrodes in the SV.
3.5 | Statistical analysis
After discussion with the University Hospital Birmingham's statisti-
cian, statistical analysis was not thought to be beneficial or possible
given the heterogeneity of the methodology, reporting outcomes, and
results (some studies pooling averages as opposed to giving individual
scores).
4 | DISCUSSION
Of the 115 patients, 114 showed improvement in hearing which was
demonstrated across a variety of audiometric outcomes (see Table 3)
compared to baseline after cochlear implantation. Poor outcomes
were noted in only 4 cases who also happened to have secondary
AIED (3 ANCA-associated vasculitis, 1 Cogan's syndrome)26,36; how-
ever, it may be relevant to note that 3 of these had chronic otitis
media which can cause difficulties in cochlear implantation.37 Addi-
tionally, the hearing assessments conducted in these cases were in
the early post-implant period (1 case less than 3 months) or not men-
tioned (2 cases). Despite the heterogeneity of the studies, the primary
outcome of this systematic review was achieved and revealed that
post-CI outcomes in AIED are largely positive.
4.1 | Clinical and research findings
Interestingly, although it is commonly quoted that up to 30% of
patients have secondary AIED,2,3,38 our study found the converse,
with only 33% of patients having primary AIED, with the remaining
majority having secondary causes. This difference may be due to a
number of reasons. Firstly, the data from these older studies may be
outdated. Alternatively, secondary AIED might progress more often to
needing a CI, so that we are selecting a more severe subset of the
total sample.
Currently there are different schools of thought surrounding opti-
mum time for cochlear implantation in AIED; for example, Cacco and
Aftab conclude that earlier cochlear implantation can be beneficial to
reduce the morbidities of long-term immunosuppressant in attempts
to preserve hearings.8,39 In reality, the optimum time will likely differ
on a case-by-case basis. We found a range of 1 month to 10 years
from deafness to cochlear implantation, although the majority seemed
to take place within 2 years. Time to implantation did not seem to
worsen post-operative outcomes. Malik et al found a difference
between subgroups, with some subtypes of secondary AIED (namely
Cogan's syndrome and relapsing polychondritis) progressing to deaf-
ness quicker than primary AIED (P < .001), but interestingly other cau-
ses of secondary AIED had a slower decline when compared to
primary AIED.11 This may affect the clinician's decision-making sur-
rounding the optimum time frame in preoperative counseling of
patients with different types of AIED. We have not been able to carry
out subgroup analyses in our study to support or challenge this claim
as some of the studies had mixed primary and secondary AIED
populations, but reported their information as a pooled average of
both groups.
Intra-operatively, a variety of CIs were used. Of the studies that
reported electrode insertions, all were fully inserted except for four
years in whom partial insertion was achieved (1 PAN, 1 Primary AIED,
1 Relapsing Polychondritis, 1 unspecified).9,10,40,41 Although it is
thought that full insertion of electrodes show better hearing out-
comes post-operatively,8,11 overall all patients receiving partial inser-
tion in this group still received significant improvement in hearing,
with improvement of hearing thresholds from a severe or profound
level to a mild-moderate hearing loss on aided audiometry.
Salahaldin41 noted an excellent response post-operatively from the
partially inserted left ear (speech discrimination score [SDS] of 100%
at 70 dB at 5 years), which superseded the fully inserted right ear
(SDS of just 50% at 90 dB at 1 year).
Theoretically, osteoneogenesis inside the cochlea could lead to
an increase in electrical impedance over time, resulting in reduced CI
efficiency and function. However, of the 85 patients (10 studies) in
this review that were reported with consecutive audiometric data
post-operatively (or compared short term with long term follow-up
data), 30%8,23,25,35 (26 patients) showed improvement in CI out-
comes over a few years, 33%11,27,42 (28 patients) reported patients
with a “generally stable” hearing level over time, 35%10,35,36
(30 patients) reported initial improvement up to 1 year and then
plateauing or mild worsening of hearing thereafter, and 1.2%
(1 patient) showed good initial response but complete deterioration
due to pain after 18 months.21 In one study,11 a further sub-group
analysis suggested that cochlear implantation may initially show
poor results in primary AIED, but then improve after 12 months;
however this studies length of follow-up (<2 years) may not be suffi-
cient as symptomatic osteoneogenesis may be a lengthier process.
That said, it is encouraging to note maintained hearing even up to
16 years post-implant.25
In general, perioperative complications were rare, with only 3.5%
(n = 4) of cases being reported within 6 months. Considering the fact
that the vast majority of patients took systemic steroids or
immunosuppresants (Table 4), it is reassuring that this percentage for
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Not stated Digisonic 15




Steroids: All except 2
AIED patients (range:
9 days to 10 years).
MTX + steroids: 3
patients
Full Nucleus 24 system: 9
patients
Med-El Combi 40+: 1
patient






6 females 31.5 4.2(0.1-11)
years
Not stated Full Nucleus CI22M: 1 (+1













Full Nucleus 24M device: 4
Nucleus 22M device: 1
Nucleus Contour model:
2
MXM Digisonic device: 5






Not stated Case 1: Cochlear
Nucleus 24




Cacco et al, 2021 1 female 35 2 months Corticosteroids and MTX Not stated HiFocus Advantage
Canzi et al, 2019 1 female 53 1.5 months Prednisolone, MTX Partial Digisonic SP
Cassis et al, 2018 1 female 24 7 weeks High dose steroid, MTX Full HiRes ultra device with
mid-scala electrode






Not stated Nucleus CI-24RE(ST)
implant
Dhanjal et al, 2014 1 male 40 4 years Prednisolone Full Nucleus CI422 electrode
Im et al, 2008 1 female 25 7 months Oral steroids, MTX Full Combi 40 device
Kamakura et al,
2017
1 male 63 Around
3 years







1 female 57 Around
3 years
Corticosteroids, MTX Full Nucleus CI24R device
Kontorinis et al,
2010





Not stated Not stated
Low et al, 2019 1 female 23 4 months Oral & IT steroids,
hyperbaric oxygen,
cyclophosphamide
Not stated HiRes 90K HiFocus Mid-
Scala
Low et al, 2000 1 male 35 10 years Oral steroids Full Nucleus 22
Malik et al, 2012 13 males 54.53 (24-84) Oral steroids: 7 Full except 2 Not stated
(Continues)
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wound complication in AIED is not higher than that seen in overall CI
cases (1-8%).43 Longer-term complications did develop as mentioned
in the results section. Patients should therefore be counseled that in
rare occasions, facial pain or device failure may develop, and that






















Mowry et al, 2017 1 female 49 15 months Steroids, IVIg,
plasmapheresis
Not stated Nucleus 24 RE with
Contour Advance
electrode
Patrizia et al, 2011 1 female 29 12 months Steroids and AZA
(initially diagnosed as
having Cogan's)
not stated Clarion 1.2







Prednisolone in one case,
and prednisolone with
cyclosporin in 2 cases
Not stated Cases 1, 2, 4 and 5:
Nucleus 24
Case 3: Nucleus 22
Salahaldin et al,
2010







1 female 18 4 years Not stated Not stated Nucleus Esprit 3G





1 female 4 6 months Prednisolone Not stated Nucleus 24C
Sydlowski et al,
2014
1 female 26 6 months Oral prednisolone, IT
steroids
Not stated Nucleus Freedom
Contour Advance
CI24RE(CA)
Wang et al, 2010 7 males
18 females


































Abbreviations: AZA, Azathioprine; IT, Intratympanic; IVIg, Intravenous Immunoglobulin; MP, Methylprednisolone; MTX, Methotrexate; ST, Scala Tympani;
SV, Scala Vestibuli.
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4.2 | Limitations of this study
There are several limitations to this systematic review. Firstly, we
report pooled results from a range of single case or small sized studies.
This is compounded by the heterogeneity between and within stud-
ies for follow-up duration (range 0-180 months), type of audiologi-
cal outcome (Table 5), reporting of intra-operative technique and
findings, and post-operative complications and treatment response.
As highlighted in Gaylor's meta-analysis of CIs in 2013,44 longer
follow-up durations are essential for properly assessing hearing out-
comes. This heterogeneity therefore precluded subgroup compari-
sons such as hearing outcomes in bilateral CIs vs unilateral CI, or
primary vs secondary AIED. Furthermore, given the relatively small
sample size (115 patients), our findings may not accurately reflect
true values for AIED. For example, only one study explicitly
reported a considerable improvement in quality of life after CI,45
however given the vast majority of patients obtaining improvement
in hearing post-operatively, the true impact to quality of life is likely
to be much greater.
Further research is required into the long-term effects of CI in
AIED patients, and particularly among the different etiologies. Future
publications should be mindful in reporting data as individual patient
level where possible as opposed to averages to allow for subgroup
analyses, and should consider extended follow-up durations to moni-
tor for deterioration in hearing and to widen our understanding of
long-term prognosis. Although difficult to organize, internationally,
pre- and post-audiometric outcomes should be standardized at least
within single centers to reduce heterogeneity between studies, and
therefore improve our understanding of CI efficacy over time.
5 | CONCLUSION
Cochlear implantation in autoimmune inner ear disease provides mar-
ked improvement in hearing for the majority of patients, which is
maintained long term. Benefit is reported in both primary and second-
ary AIED, however the latter subgroup may be at a higher risk of poor
response. Surgically, despite patients often taking concurrent steroids
and the potential presence of cochlea ossification, complication rates
are comparable to implantation in non-autoimmune hearing loss
patients, and appear to be stable. Early CI may therefore be a valid
management option in AIED, as it can provide excellent long lasting
hearing to patients.
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TABLE 5 Reported outcomes per study
Reported outcomes Study
Arthur Boothroyd isophonemic



















Malik (2012), Sydlowski (2014),
Kamakura (2017)







AlHelali (2019), Seo (2012),
Salahaldin (2010)
Free Field testing (FF) Salahaldin (2010)
Hearing in noise sentence test
presented in quiet (HINT-Q)
Malik (2012)
Hochmair-Schulz-Moser







Pure Tone Audiogram (PTA) Abou-Elhmd (1996), Canzi
(2019), Cacco (2021), Cheng
(2010)
Speech In Noise (SIN) Sydlowski (2014)
Sentence Recognition Score
(SRS)
Canzi (2019), Bacciu (2015), Im
(2008)
Speech intelligibility AlHelali (2019)
Speech Tracking (ST) Kontorinis (2010), Quaranta
(2002)
Test di Identificazione Parole






Word Intelligibility by Picture
Identification Test (WIPI)
Sweetow (2005)
Word Recognition Score (WRS) Bovo (2011), Sweetow (2005),
Cacco (2021), Kamakura
(2017), Bacciu (2015), Cassis
(2018), Psillas (2007)
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APPENDIX A: Search strategy used for MEDLINE/pubmed and
EMBASE. The same search terms were used for other databases
1 “Cochlear implant*”.mp.
2 Cochlear Implantation/ or Cochlear Implants/
3 1 or 2
4 exp Vasculitis/
5 Vasculitis.mp.
6 “Giant cell arteritis”.mp.
7 “temporal arteritis”.mp.
8 “Wegener's granulomatosis”.mp.










19 (“Primary angiitis” adj3 “central nervous system”).mp.
20 Autoimmune.mp.
21 “Addison's disease”.mp.





27 “Inflammatory bowel disease”.mp.
28 “Graves' disease”.mp.
29 “Pernicious an?emia”.mp.






36 Connective Tissue Disease.mp.
37 Sjogren*.mp.
38 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or
16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or
27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37
36 3 and 38
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